Awaiting product image

Ihc – Breast Cancer Prognosis Profile # 2b (Er, Pr, Her2neu, Dna Ploidy)

₹6,000.00

15 minutes
Categories: ,

This diagnostic panel combines immunohistochemistry (IHC) and flow cytometry or image cytometry techniques to assess key biological markers and genetic characteristics of breast cancer cells. The test includes:

• ER (Estrogen Receptor): Determines if the tumor grows in response to estrogen.
• PR (Progesterone Receptor): Evaluates the tumor’s response to progesterone.
• HER2neu: Identifies overexpression or amplification of the HER2 protein, which can drive aggressive cancer growth.
• DNA Ploidy: Assesses the amount of DNA in cancer cells to determine whether they are diploid (normal) or aneuploid (abnormal), which can indicate tumor aggressiveness.

Together, these markers provide valuable information for understanding tumor behavior, guiding treatment decisions, and assessing prognosis.

Enquiry Here

    Description

    Why It’s Done:

    This test panel is used to:
    • Determine hormone receptor status (ER/PR) to guide hormonal therapy decisions.
    • Evaluate HER2 status, which is critical for selecting HER2-targeted therapies such as trastuzumab.
    • Assess DNA ploidy, an indicator of tumor cell genomic stability — aneuploid tumors tend to behave more aggressively and may be associated with poorer prognosis.
    • Support personalized treatment planning based on the biological characteristics of the tumor.
    By combining receptor status with genetic profiling (DNA content), the test offers a more comprehensive assessment of breast cancer prognosis.

    Preparation:

    • No special preparation is required from the patient.
    • The test is performed on tissue samples obtained via biopsy or surgical removal of the tumor.
    • If undergoing a biopsy, the healthcare provider may provide instructions related to fasting, medications, or other pre-procedure requirements

    Related products